Anesthetic biotransformation and renal function in obese patients during and after methoxyflurane or halothane anesthesia.
Anesthetic biotransformation and renal function were studied in obese adult patients (148 plus or minus 8 kg; mean plus or minus SE) anesthetized for three hours with 60 per cent nitrous oxide plus either methoxyflurane or halothane for elective jejunoileal small-bowel-bypass operations. There was no evidence of persistent renal dysfunction in any patient postoperatively, but serum osmolality was elevated 72 hours after methoxyflurane anesthesia. Urine concentrating ability was not determined. Peak serum ionic fluoride concentration was 55.8 plus or minus 5.8 muM/1 two hours after discontinuation of methoxyflurane. Urinary ionic fluoride and oxalate excretions increased postoperatively. Compared with previously reported data from nonobese patients, serum ionic fluoride concentrations in obese patients increased more rapidly during methoxyflurane anesthesia and peaked higher and sooner after discontinuation of methoxyflurane. The peak serum ionic fluoride concentration was 10.4 plus or minus 1.5 muM/1 at the conclusion of halothane anesthesia, significantly more than the corresponding value in nonobese patients. Intraoperative liver biopsies from 23 of 27 patients showed moderate to severe fatty metamorphosis. Fatty liver infiltration may have increased hepatic anesthetic uptake and exposed more methoxyflurane or halothane to hepatic microsomal enzymes. The more rapid elevation and higher peak levels of serum ionic fluoride following methoxyflurane, and to a lesser extent following halothane, may reflect increased anesthetic biotransformation in obese compared with nonobese patients. To avoid excessive serum ionic fluoride elevations the authors recommended limiting low-dose methoxyflurane anesthesia delivered to obese patients with potential fatty liver infiltration to no more than three hours.
D000759:Adjuvants, Anesthesia; D000328:Adult; D000769:Anesthesia, Inhalation; D001707:Biopsy, Needle; D001711:Biotransformation / Q000187:drug effects; D005234:Fatty Liver / Q000473:pathology; D005459:Fluorides / Q000097:blood / Q000652:urine; D006221:Halothane / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D007677:Kidney Function Tests; D008099:Liver / Q000473:pathology; D008733:Methoxyflurane / Q000378:metabolism; D009609:Nitrous Oxide; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology* / Q000601:surgery; D010070:Oxalates / Q000652:urine; D014527:Uric Acid / Q000097:blood
D000759:Adjuvants, Anesthesia; D010070:Oxalates; D014527:Uric Acid; D008733:Methoxyflurane; D009609:Nitrous Oxide; D005459:Fluorides; D006221:Halothane